Skip to content
Open access

Beta-Blocker Use After Acute Myocardial Infarction

Aug 2026 · JACC: Advances · Vol 5, pp. 103168 · 0 citations · 48 references
Medicine

TL;DR

Among patients with AMI complicated by HF, in-hospital BB use was associated with lower 1-year adverse outcomes risk in HFrEF/HFmrEF, but not in HFpEF.

Abstract

Background Beta-blocker (BB) benefits after acute myocardial infarction (AMI) may differ by heart failure (HF) phenotype in the contemporary reperfusion era. Objectives The authors evaluated associations of in-hospital BB therapy with 1-year outcomes after AMI complicated by HF, stratified by left ventricular ejection fraction phenotype. Methods We analyzed 5,557 patients with AMI complicated by HF from the Tianjin Coronary Artery Disease Specialized Database, including 3,962/5,557 (71.3%) with HF with preserved ejection fraction (HFpEF) and 1,595/5,557 (28.7%) with HF with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF). The primary endpoint was a 1-year composite of cardiac death or HF rehospitalization. We assessed associations using inverse probability of treatment weighting, Cox models, and competing risk analyses. Sensitivity analyses comprised propensity score matching, win ratio, and time-stratified Cox models. Results Overall, 859/5,557 patients (15.5%; 95% CI: 14.5%-16.4%) reached the primary endpoint by 1 year; median follow-up was 1,566 days (IQR: 882-2,354). Interaction by HF phenotype was significant (P = 0.034). After adjustment, BB therapy was associated with lower primary endpoint risk in HFrEF/HFmrEF (adjusted HR [aHR]: 0.590; 95% CI: 0.438-0.795; P < 0.001), but not in HFpEF. BB therapy was also associated with lower risks of all-cause death (aHR: 0.577; 95% CI: 0.395-0.841; P = 0.004) and cardiac death (aHR: 0.536; 95% CI: 0.349-0.823; P = 0.004) in HFrEF/HFmrEF. Sensitivity analyses yielded consistent findings. Conclusions Among patients with AMI complicated by HF, in-hospital BB use was associated with lower 1-year adverse outcomes risk in HFrEF/HFmrEF, but not in HFpEF.

Read PDF

Similar papers

Open access Oct 2026

BETA-BLOCKER THERAPY AFTER MYOCARDIAL INFARCTION IN PATIENTS WITHOUT HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Beta-blocker (BB) therapy after myocardial infarction (MI) in patients with reduced left ventricular ejection fraction (LVEF) is well established. However, recent randomised controlled trials (RCTs) in post-MI patients without significantly impaired LVEF have yielded conflicting results. This meta-analysis aimed...

I. F. Arba, A. Primiputri, M. B. A. Paramarta et al. · 0 citations
Sep 2026

Risk-Score Guided Estimation of Absolute Benefit From Beta-blockers after Myocardial Infarction in Patients Without Heart Failure.

The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.

H. Caglar, T. Holmager, A. Kristensen et al. · 0 citations
Review Open access Sep 2026

BETA-BLOCKERS DISCONTINUATION AFTER MYOCARDIAL INFARCTION REFERRING TO EJECTION FRACTION

The clinical role of beta-blocker therapy after myocardial infarction (MI) has been debated extensively as the landscape of post-MI management has evolved. Historically, beta-blockers were established as a cornerstone of secondary prevention following landmark randomized controlled trials conducted in the 1980s (Hjalma...

Krzysztof Machnik, B. Tekieli, Wojciech Krzysztof Cyran et al. · 0 citations
Review Open access Sep 2026

Beta-Blocker Therapy After Acute Myocardial Infarction

Historically, beta-blockers have long represented a cornerstone of secondary prevention after acute myocardial infarction (AMI). However, the transition to the modern era of early reperfusion and potent pharmacotherapy has questioned their universal efficacy, particularly in patients without post-AMI left ventricular d...

Chiara Cosentino, L. Cutore, Carmelo Raffo et al. · 0 citations
Review Sep 2026

Impact of beta-blockers on cardiovascular outcomes in myocardial infarction patients with preserved or mildly reduced ejection fraction: Systematic review and meta-analysis of randomized trials.

In this meta-analysis of randomized clinical trials, beta-blocker use was not associated with a significant reduction in the primary composite outcome or in mortality or reinfarction, and should be interpreted with caution in the context of an overall neutral result.

L. D. Neira-Chunga, D. Moncada-Gutiérrez, G. Vásquez-Tirado et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.